Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 3/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | CETP | P11597 | 1/20 | 0.42 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.42 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5351369 | 0.91 | EGFR (0.59) | EGFRSRCGSK3BGSK3AABCG2 | |
| SCHEMBL5350239 | 0.88 | MEN1 (0.52) | EGFRGSK3BABCG2TTBK1TTBK2 | |
| SCHEMBL5356576 | 0.88 | GSK3B (0.56) | EGFRGSK3BABCG2CETPTTBK1 | |
| SCHEMBL14355886 | 0.87 | GSK3B (0.54) | EGFRGSK3BABCG2MMP2MMP9 | |
| SCHEMBL5785011 | 0.85 | EGFR (0.54) | EGFRSRCTTBK1TTBK2 | |
| Hydrochloric Acid SCHEMBL5350968 | 0.84 | EGFR (0.53) | EGFRSRCTTBK1TTBK2 | |
| Hydrochloric Acid SCHEMBL5351366 | 0.84 | EGFR (0.53) | EGFRSRCTTBK1TTBK2 | |
| SCHEMBL5348949 | 0.81 | ALK (0.52) | EGFRGSK3BABCG2TTBK1TTBK2 | |
| SCHEMBL5359718 | 0.81 | EGFR (0.62) | EGFRSRCGSK3BABCG2TTBK1 | |
| SCHEMBL5353750 | 0.80 | EGFR (0.55) | EGFRSRCTTBK1TTBK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7294633-B2 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | NOVARTIS AG (CH) | 2007-11-13 | — | — | US | claimed |
| EP-1390371-B1 | OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS | NOVARTIS AG (CH) | 2006-03-08 | — | — | EP | claimed |
| US-20040152892-A1 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | NOVARTIS AG (CH) | 2004-08-05 | — | — | US | claimed |
| EP-1390371-A1 | OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS | Novartis AG (CH) | 2004-02-25 | — | — | EP | claimed |
| WO-2002092603-A1 | OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS | NOVARTIS AG (CH) | 2002-11-21 | — | — | WO | claimed |
| US-7294633-B2 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | NOVARTIS AG (CH) | 2007-11-13 | — | — | US | disclosed |
| EP-1390371-B1 | OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS | NOVARTIS AG (CH) | 2006-03-08 | — | — | EP | disclosed |
| US-20040152892-A1 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | NOVARTIS AG (CH) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152892-A1 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | DPYD, COXFA4L2, MSH2 | EGFR 1321/4885SRC 1125/4885GSK3B 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.